Q3 2026 EPS Estimates for Novartis AG (NYSE:NVS) Cut by Zacks Research

Novartis AG (NYSE:NVS) – Equities researchers at Zacks Research lowered their Q3 2026 earnings estimates for shares of Novartis in a research note issued to investors on Monday, September 30th. Zacks Research analyst E. Bagri now anticipates that the company will post earnings per share of $2.37 for the quarter, down from their previous forecast of $2.38. The consensus estimate for Novartis’ current full-year earnings is $7.50 per share. Zacks Research also issued estimates for Novartis’ FY2026 earnings at $8.94 EPS.

Novartis (NYSE:NVS) last posted its earnings results on Thursday, July 18th. The company reported $1.97 EPS for the quarter, topping the consensus estimate of $1.87 by $0.10. Novartis had a net margin of 33.76% and a return on equity of 34.56%. The firm had revenue of $12.87 billion for the quarter, compared to analysts’ expectations of $12.24 billion. During the same quarter last year, the firm earned $1.83 EPS.

Several other equities research analysts have also issued reports on NVS. The Goldman Sachs Group restated a “neutral” rating and set a $121.00 price target (up previously from $119.00) on shares of Novartis in a research note on Thursday, September 5th. Bank of America lowered shares of Novartis from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $135.00 to $130.00 in a research note on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Novartis in a research note on Friday, July 19th. Barclays upgraded shares of Novartis to a “strong sell” rating in a research note on Monday, June 24th. Finally, Jefferies Financial Group lowered shares of Novartis from a “buy” rating to a “hold” rating in a research note on Tuesday, September 3rd. One analyst has rated the stock with a sell rating, seven have given a hold rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $120.70.

Novartis Price Performance

Novartis stock opened at $113.77 on Thursday. The company’s 50 day moving average price is $115.35 and its two-hundred day moving average price is $106.41. The company has a quick ratio of 0.72, a current ratio of 0.93 and a debt-to-equity ratio of 0.47. Novartis has a 52 week low of $92.19 and a 52 week high of $120.92. The stock has a market cap of $232.55 billion, a P/E ratio of 15.35, a P/E/G ratio of 1.73 and a beta of 0.57.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Dimensional Fund Advisors LP grew its stake in Novartis by 23.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 7,407,692 shares of the company’s stock valued at $788,626,000 after buying an additional 1,389,610 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Novartis by 1.2% in the 4th quarter. Wellington Management Group LLP now owns 4,746,599 shares of the company’s stock valued at $479,264,000 after purchasing an additional 54,683 shares during the period. Janus Henderson Group PLC boosted its holdings in Novartis by 0.6% in the 1st quarter. Janus Henderson Group PLC now owns 2,568,728 shares of the company’s stock valued at $248,473,000 after purchasing an additional 16,015 shares during the period. Principal Financial Group Inc. increased its holdings in shares of Novartis by 0.6% in the first quarter. Principal Financial Group Inc. now owns 2,523,334 shares of the company’s stock worth $244,082,000 after purchasing an additional 14,686 shares during the period. Finally, Mondrian Investment Partners LTD raised its position in shares of Novartis by 40.1% in the first quarter. Mondrian Investment Partners LTD now owns 2,065,739 shares of the company’s stock worth $199,819,000 after buying an additional 590,830 shares in the last quarter. 13.12% of the stock is currently owned by hedge funds and other institutional investors.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.